Candelaria Gomez Manzano News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Four MD Anderson researchers elected AAAS Fellows

In recognition of their significant achievements in the realm of cancer care and research, four researchers at The University of Texas MD Anderson Cancer Center

United statesCandelaria gomez manzanoKali maDrug administrationAmerican association for the advancement of scienceNeoplasm initiativeAnderson cancer neuroscience programUniversity of texas md anderson cancer centerCancer centerAmerican associationSattva neelapuExperimental radiation oncologyCancer metabolism research programRadiation oncologyAcquired resistanceGlioblastoma moon

Intratumoural viral delivery improves glioblastoma survival

“Injecting a virus into a patient’s brain tumour” combined with immunotherapy improved glioblastoma survival outcomes in a clinical trial.

United statesJuan fueyoCandelaria gomez manzanoFrederick langMerck coDivision of cancer medicineMd anderson cancer centerNature medicineCancer medicineCancer centerUniversity of texas

Engineered Virus and Immunotherapy Combo Safe, Improves Glioblastoma Outcomes

Engineered Virus and Immunotherapy Combo Safe, Improves Glioblastoma Outcomes
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesJuan fueyoFrederick langCandelaria gomez manzanoMerck coDnatrix incUniversity of texas md anderson cancer centerUniversity of torontoCancer centerNature medicine

Combined delivery of engineered virus with im

Intratumoral delivery of an engineered oncolytic virus (DNX-2401) targeting glioblastoma (GBM) cells combined with subsequent immunotherapy was safe and improved survival outcomes in a subset of patients with recurrent GBM, according to results from a multi-institutional Phase I/II clinical trial co-led by researchers at The University of Texas MD Anderson Cancer Center and the University of Toronto.

University of texasUnited statesJuan fueyoCandelaria gomez manzanoFrederick langUniversity of torontoDnatrix incMerck coAnderson cancer centerNature medicine

Combination approach is safe, improves survival outcomes in a subset of glioblastoma patients

Intratumoral delivery of an engineered oncolytic virus (DNX-2401) targeting glioblastoma (GBM) cells combined with subsequent immunotherapy was safe and improved survival outcomes in a subset of patients with recurrent GBM, according to results from a multi-institutional Phase I/II clinical trial co-led by researchers at The University of Texas MD Anderson Cancer Center and the University of Toronto.

United statesFrederick langJuan fueyoCandelaria gomez manzanoEmily hendersonUniversity of torontoDnatrix incMerck coUniversity of texas md anderson cancer centerCancer centerNature medicineClinical trialImmune responseImmune system